This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary objectives 1.1 In conjunction with POG 9905, to compare short MTX infusion (2g/m2 over 4 hours) with a longer infusion (1g/m2 over 24 hours), primarily with respect to efficacy and secondarily with respect to toxicity. 1.2 In conjunction with POG 9905, to determine in a randomized trial, if a delayed multi-drug intensification, administered in the context of intensive anti-metabolite therapy, will improve outcome for children with ALL. Modern chemotherapy provides cure for 60-65% of children with newly diagnosed acute lymphoblastic leukemia (1,2). Favorable subgroups have much superior cure rates approaching 85% (3,4,5). In addition to age and white count risk groups, many studies have indicated a prognostic role for cytogenetic analysis of lymphoblasts (6). Analysis of data from ALinC 14 (POG 8602) indicates that favorable outcome may be best predicted by recognition of patients whose blasts contain simultaneous trisomies of chromosomes 4 and 10 (7). An interim analysis of ALinC 16 (POG 9201) continues to support this finding (POG Agenda Spring 1999). These patients continue to have an excellent prognosis when treated on an antimetabolite-based regimen that includes six courses of a 24-hour infusion of methotrexate. Given ever increasing economic pressures to limit hospitalizations, the recently completed ALinC 17 pilot protocol, (9705 and the amended 9201 protocol) explored the administration of IV MTX as a shorter, potentially out-patient, infusion of 2 gm/m2 over four hours. This pattern of MTX administration has been used at St Jude Children's Research Hospital for several years (8). Based on published data, this two gram infusion will maintain a plasma MTX concentration of > 0.2 micromolar for approximately 40 hours, as will a 200 mg/m2 dose infused over 20 minutes, followed by an 800 mg/m2 infusion over 23.6 hours. Note, though, that regardless of the similarities in the time above 0.2 micromolar, the pharmacokinetic differences between the two infusions are significant. The short infusion produces a much higher peak concentration, an area under the curve (AUC) of different shape, and never achieves a steady state concentration. Given that the schedule of MTX administration may be as, if not more important than the dose (9), these pharmacokinetic differences may be important to both the efficacy and toxicity of parenteral MTX therapy (10-12). Standardized suggestions for hydration, MTX and leucovorin administration are included in the protocol as hydration may also have a dramatic affect on MTX plasma concentrations and drug clearance (13). POG 9904 will compare these two methods of administration of the MTX infusions for the subgroup of patients who are classified as standard risk patients by the NCI Risk Group classification and in addition, have either: 1) trisomies of chromosomes 4 and 10 or 2) have the TEL/AML1 translocation (see below for rationale). Patients will be randomized to either a short intravenous infusion of MTX (2 gm/m2 over 4 hrs) versus standard MTX (1 gm/m2 over 24 hrs) to determine whether an outpatient based regimen can be given without a decrease in efficacy or increase in toxicity. Data from POG 9904 and 9905 will be pooled for statistical analysis of efficacy and toxicity.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Al-Sofiani, Mohammed E; Yanek, Lisa R; Faraday, Nauder et al. (2018) Diabetes and Platelet Response to Low-Dose Aspirin. J Clin Endocrinol Metab 103:4599-4608
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Aboud, Katherine S; Barquero, Laura A; Cutting, Laurie E (2018) Prefrontal mediation of the reading network predicts intervention response in dyslexia. Cortex 101:96-106
Kattan, Meyer; Bacharier, Leonard B; O'Connor, George T et al. (2018) Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. J Allergy Clin Immunol Pract 6:1596-1603.e6
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Salemi, Parissa; Skalamera Olson, Julie M; Dickson, Lauren E et al. (2018) Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI. J Clin Endocrinol Metab 103:158-168
Robert Braši?, James; Mari, Zoltan; Lerner, Alicja et al. (2018) Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. Int J Phys Med Rehabil 6:
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866

Showing the most recent 10 out of 1014 publications